← Back to Search

Other

STSA-1002 subcutaneous injection: dose 1 (First cohort) for Vasculitis

Phase 1
Waitlist Available
Led By Martin K Kankam, Doctor
Research Sponsored by Staidson (Beijing) Biopharmaceuticals Co., Ltd
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up pre-dose; after dose 8hours, 24hours, 48hours, 72hours, 96hours, 120hours, 168hours, 336hours, 504hours, 840hours, 1176hours
Awards & highlights

Study Summary

This trial studies the safety and effectiveness of a new drug in healthy people to see how it works and is tolerated.

Eligible Conditions
  • Vasculitis

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~pre-dose; after dose 8hours, 24hours, 48hours, 72hours, 96hours, 120hours, 168hours, 336hours, 504hours, 840hours, 1176hours
This trial's timeline: 3 weeks for screening, Varies for treatment, and pre-dose; after dose 8hours, 24hours, 48hours, 72hours, 96hours, 120hours, 168hours, 336hours, 504hours, 840hours, 1176hours for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Abnormal clinical laboratory values as assessed by toxicity grading scale for healthy adult and adolescent volunteers enrolled in preventive vaccine clinical trials (blood hematology, blood chemistry, urinalysis, etc.)
Abnormal electrocardiogram (ECG): heart rate, PR and QT intervals, QTcF and QRS duration
Abnormal physical examination
+12 more
Secondary outcome measures
Change from baseline in concentration of free C5a
anti-drug antibody

Trial Design

2Treatment groups
Experimental Treatment
Group I: STSA-1002 subcutaneous injection: dose 2 (Second cohort)Experimental Treatment1 Intervention
Group II: STSA-1002 subcutaneous injection: dose 1 (First cohort)Experimental Treatment1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
STSA-1002 subcutaneous injection
2023
Completed Phase 1
~20

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

Staidson (Beijing) Biopharmaceuticals Co., LtdLead Sponsor
20 Previous Clinical Trials
1,153 Total Patients Enrolled
1 Trials studying Vasculitis
100 Patients Enrolled for Vasculitis
Martin K Kankam, DoctorPrincipal InvestigatorAltasciences Clinical Kansas, Inc.

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is the age cutoff for this research endeavor restricted to those aged 50 or under?

"Patients wishing to participate in this experiment must be aged between 21 and 57. For those younger, there are 6 other trails available while people 65 years or older can choose from 35 options."

Answered by AI

Has the Federal Drug Administration sanctioned STSA-1002 subcutaneous injection: dose 1 (First cohort) for usage?

"As this is an early-stage Phase 1 trial, the safety of STSA-1002 subcutaneous injection: dose 1 (First cohort) has been assigned a score of one due to the limited amount of data available."

Answered by AI

Are there any unfilled positions in this experiment for participants?

"Contrary to what is listed on clinicaltrials.gov, this study has ceased recruiting patients as of January 18th 2023. Nonetheless, there are still 38 other trials that require participants for their research and development initiatives."

Answered by AI

Do I meet the necessary prerequisites for participating in this medical trial?

"This clinical trial is accepting 20 individuals, with ages ranging from 21 to 57 years old and currently suffering from antineutrophil cytoplasmic antibody associated vasculitis. Eligible participants must also have a healthy body mass index (21-31 kg/m2) that weighs in between 50-93 kilograms, agree to use highly effective contraceptive measures during the study and for 6 months after its completion; these include double barrier methods of contraception or hormonal contraceptives if they are females of non-childbearing potential who had been sterilized at least 6 months before screening - Follicle Stimulating Hormone levels should be ≥"

Answered by AI
~10 spots leftby Mar 2025